The prognostic value of cognitive functioning in the survival of patients with high-grade glioma

Neurology

Volumn 61, Issue 12, 2003, Pages 1796-1798

  Klein, M ^a   Postma, T J ^a   Taphoorn, M J B ^b   Aaronson, N K ^c   Vandertop, W P ^a   Muller, M ^c   Van Der Ploeg, H M ^a   Heimans, J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; COGNITION; COGNITIVE DEFECT; DIAGNOSTIC VALUE; FEMALE; GLIOMA; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0347994916     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000098892.33018.4C     Document Type: Article

References (9)

1. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06, Int J Radiat Oncol Biol Phys 1998;40:51-55.
2. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767-775.
3. Curran WJ, Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;704-710.
4. Thomas R, O'Connor AM, Ashley S. Speech and language disorders in patients with high grade glioma and its influence on prognosis. J Neurooncol 1995;23:265-270.
5. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000;18:646-650.
6. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002;20:3445-3453.
7. Klein M, Taphoorn MJ, Heimans JJ, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol 2001;19:4037-4047.
8. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52:737-743.
9. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncol 2003;5:89-95.